Body Impedance Analysis to Detect ICUAW (BIAMI)

Charité University Medicine Berlin

Status: Completed

Conditions: Critical Illness

Treatments: Diagnostic Test: Body Impedance Analysis

Study type: Observational

Funder types: Other

Identifiers

NCT05572138

BIAMI

Details and patient eligibility

About

The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated.

The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.

Full description

Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of neuromuscular organ dysfunction. It develops in approximately 40% of all ICU patients, which corresponds to at least 1.2 million patients annually in Germany. All these patients face a wide spectrum of sequelae and increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is early severe muscle atrophy, which is as high as 17% in the first days after ICU admission.

ICUAW is currently diagnosed by the MRC score, which is assessed by the sum of manual muscle strength test results in 12 muscle groups (sum score). Manual muscle testing (MMT) is not possible during the early phase in critical illness in most patients due to coma, delirium, and/or injury. In addition, there is a possible discrepancy by different observers. As a result, early detection of ICUAW may be inadequate in most patients and unreliable during critical illness.

Measurement by BIA is reproducible, so differences in measurement can be attributed to changes in clinical condition. Body impedance analysis thus demonstrates a means of objective measurement.

Thus, the study aims to counteract the long-term consequences of ICUAW through early detection of ICUAW by allowing countermeasures to be taken earlier.

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged ≥ 18 years with ventilatory support within 36 hours from ICU admission.

Exclusion criteria

• With a language barrier
• Patients with pacemaker or other electronic implant
• Expected death or discontinuation of life-sustaining measures.
• Not walking independently before hospitalization (gait aids allowed)
• Allergy to electrode gel
• BIA or ultrasound not technically feasible due to e.g. extensive wounds, skin rash or bandages

Trial design

62 participants in 1 patient group

Critically ill patients

Treatment:

Diagnostic Test: Body Impedance Analysis